In an acute oral glucose challenge, LASSBio-1986 improved glucose tolerance and increased tissue glycogen stores, whereas in a dexamethasone-induced insulin-resistance model it ameliorated insulin sensitivity, normalized lipid profile, reduced oxidative stress markers, and rebalance pro- and anti-inflammatory cytokines, in several endpoints paralleling the effects of dapagliflozin. The gene discussed is INS; the disease is Insulin resistance.